Welcome to our dedicated page for CERo Therapeutics SEC filings (Ticker: CERO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Clinical-stage biotechnology companies generate SEC filings that reveal critical information about their financial runway and operational progress. For CERo Therapeutics Holdings (CERO), these documents provide transparency into how the company allocates capital toward its chimeric engulfment receptor research program while navigating the regulatory pathway for CER-1236.
Quarterly and Annual Reports (10-Q and 10-K filings) detail CERo's research and development expenditures, cash position, and operational burn rate—metrics essential for evaluating how long the company can fund clinical trials before requiring additional financing. These filings also disclose clinical trial progress, partnership arrangements, and risk factors specific to early-stage drug development.
Material Event Disclosures (8-K filings) announce significant developments as they occur: financing transactions, clinical milestones, patent developments, and changes in corporate structure. For a company in Phase 1 trials, 8-K filings often contain the most time-sensitive information about regulatory interactions and trial progress.
Registration Statements (S-1, S-3) and Prospectus Supplements (424B3) document equity offerings and financing activities. Clinical-stage biotechs frequently raise capital through public offerings, and these filings specify terms, use of proceeds, and dilution impact on existing shareholders.
Proxy Statements (DEF 14A) disclose executive compensation, board composition, and shareholder voting matters. For investors evaluating management alignment with shareholder interests, these documents provide essential governance information.
Our AI-powered summaries help you quickly understand what each CERo Therapeutics filing contains without reading dozens of pages of regulatory language. Track insider transactions through Form 4 filings to see when executives and directors buy or sell shares.
Cero Therapeutics Holdings, Inc. filed a Prospectus Supplement updating its S-1 covering 12,500,000 shares of common stock, incorporating a Current Report on Form 8-K.
The update discloses that a Nasdaq Hearings Panel denied continued listing of the common stock, with trading on Nasdaq to be suspended at the open on October 31, 2025. The company has requested review by the Nasdaq Listing and Hearing Review Council and has begun the process to trade on the OTC Markets, noting that OTC venues are typically less liquid and may adversely affect trading price and volume. Cero is also considering other exchange listings.
The company states it intends to continue its clinical trials, including ongoing dosing. Early observations for CER-1236 in three AML patients at an initial low dose included rapid cell expansion and no observed toxicity, and one patient continues on trial; the company plans to advance to a higher dose and is evaluating financing alternatives to fund operations.
Cero Therapeutics Holdings, Inc. filed Prospectus Supplement No. 11 to its S‑1, covering 2,100,000 shares of common stock and updating its prospectus with an attached Form 8‑K. The supplement incorporates the company’s latest disclosure into the existing offering materials.
The company reports that a Nasdaq Hearings Panel denied continued listing; CERO common stock will be suspended from trading at the open on October 31, 2025. Cero has requested review by the Nasdaq Listing and Hearing Review Council and has begun the process to trade on the OTC Markets, noting that OTC is a less liquid venue that may materially affect trading price and volume. The company is also considering other exchange listing alternatives.
Cero plans to continue its clinical trials of CER‑1236. Early observations in the first three AML patients at an initial low dose showed rapid CER‑1236 cell expansion with no toxicity; a second patient receiving three successive low doses remains on trial. The company is progressing to a planned higher dose and is reviewing cash resources and financing alternatives, with no assurance of obtaining financing.
CERO Therapeutics Holdings reported that a Nasdaq Hearings Panel denied its request for continued listing, citing noncompliance with the Nasdaq Capital Market’s minimum stockholders’ equity requirement of $2,500,000 under Rule 5550(b). As a result, CERO’s common stock will be suspended from trading on October 31, 2025.
The company has requested review by the Nasdaq Listing and Hearing Review Council and has begun the process to trade on the OTC Markets, while also considering other exchange options. CERO plans to continue its clinical trials, noting early observations for CER-1236 in initial AML patients at low dose with rapid cell expansion and no observed toxicity, and intends to proceed to higher dosing. The company is reviewing cash resources and potential financing alternatives and states there is no assurance of obtaining financing on acceptable terms, or at all.
CERo Therapeutics Holdings filed a prospectus supplement updating its S-1 that registers 2,100,000 shares of common stock. The supplement attaches recent current reports on Form 8-K.
Nasdaq prices on October 22, 2025 were $2.01 for CERO and $0.019 for CEROW. The attached 8-Ks detail a private placement: a Securities Purchase Agreement for up to $7 million of Series E convertible preferred stock (stated value $1,000 per share). An SPA amendment increased the initial closing to approximately $2.25 million, with 3,816 Series E shares issued, and leaves $4.75 million available for additional closings. The fixed conversion price is $4.1625 per share, with stockholder approval mechanics and potential price adjustments for future issuances. Holders of existing Series C and D preferred consented to pari passu ranking and their conversion prices were set at $1.76. The company agreed to file a registration statement to register for resale the common stock issuable upon conversion of the Series E preferred.
CERO Therapeutics Holdings filed Prospectus Supplement No. 4 to its Form S-1, covering 12,500,000 shares of common stock. The supplement incorporates recent Form 8-Ks from September 22, October 14, and October 16, 2025.
The October 14 and 16 updates detail a private placement of up to $7 million of Series E convertible preferred stock, including an initial closing of approximately $2.25 million for 3,816 Series E shares. The Series E has a stated value of $1,000 per share, a fixed conversion price of $4.1625 (subject to adjustments and alternate conversion pricing), and no voting rights. The company plans to seek stockholder approval to permit below-price conversions, targeting a preliminary proxy by October 31, a definitive proxy by November 30, and a meeting by December 31, 2025. The filing also notes the Series C and D preferred shares’ conversion price was reduced to $1.76.
On Nasdaq, as of October 22, 2025, CERO closed at $2.01 and CEROW at $0.019 per warrant.
CERo Therapeutics Holdings, Inc. amended its Securities Purchase Agreement to add an additional buyer and increase the Initial Closing by $500,000 to approximately $2.25 million in gross proceeds, while keeping the total financing at up to $7 million.
On October 16, 2025, the Company completed the Initial Closing, issuing 3,816 shares of Series E Convertible Preferred Stock, with $4.75 million remaining to be funded in additional closings under the agreement. Earlier, on October 14, 2025, the Company filed the Certificate of Designations establishing the Series E Preferred Stock.
The securities were issued in a private placement to accredited investors under Section 4(a)(2) and Rule 506 of the Securities Act. Upon conversion, the Series E will be exchangeable into shares of common stock as set forth in the Certificate of Designations.
CERo Therapeutics Holdings entered a Securities Purchase Agreement for a private placement of up to
Series E converts into common stock at a fixed conversion price of
The Company will seek stockholder approval to permit issuance of conversion shares below the fixed price, with targeted filing and meeting dates by
CERO Therapeutics Holdings, Inc. filed a Form 8-K reporting that it furnished an Investor Presentation dated
FAQ
What is the current stock price of CERo Therapeutics (CERO)?
What is the market cap of CERo Therapeutics (CERO)?
